Janux Therapeutics JANX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Janux Therapeutics's accounts payable?
- Janux Therapeutics (JANX) reported accounts payable of $3.38M in Q1 2026.
- How has Janux Therapeutics's accounts payable changed year-over-year?
- Janux Therapeutics's accounts payable increased by 43.6% year-over-year, from $2.35M to $3.38M.
- What is the long-term trend for Janux Therapeutics's accounts payable?
- Over 4 years (2021 to 2025), Janux Therapeutics's accounts payable has grown at a 20.3% compound annual growth rate (CAGR), from $6.77M to $14.19M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.